Factors that Predict Clinical Benefit of EGFR TKI Therapy in Patients with EGFR Wild-Type Lung Adenocarcinoma
Seo Yun Kim, Jae Kyung Myung, Hye-Ryoun Kim, Im Il Na, Jae Soo Koh, Hee Jong Baek, Cheol Hyeon Kim
Tuberc Respir Dis. 2019;82(1):62-70.   Published online 2018 Jun 19     DOI: https://doi.org/10.4046/trd.2018.0004
Citations to this article as recorded by Crossref logo
Clathrin‐mediated EGFR endocytosis as a potential therapeutic strategy for overcoming primary resistance of EGFR TKI in wild‐type EGFR non‐small cell lung cancer
Boyeon Kim, Young Soo Park, Jae Sook Sung, Jong Won Lee, Saet Byeol Lee, Yeul Hong Kim
Cancer Medicine.2021; 10(1): 372.     CrossRef
Factors affecting treatment selection and overall survival for first-line EGFR-tyrosine kinase inhibitor therapy in non-small-cell lung cancer
Yong-Jin Kim, Mark Oremus, Helen H Chen, Thomas McFarlane, Danielle Fearon, Susan Horton
Journal of Comparative Effectiveness Research.2021; 10(3): 193.     CrossRef
Cost-Effectiveness Analysis of Afatinib, Erlotinib, and Gefitinib as First-Line Treatments for EGFR Mutation-Positive Non-Small-Cell Lung Cancer in Ontario, Canada
Yong-Jin Kim, Mark Oremus, Helen H. Chen, Thomas McFarlane, Danielle Fearon, Susan Horton
PharmacoEconomics.2021; 39(5): 537.     CrossRef
A novel diagnostic system to evaluate epidermal growth factor receptor impact as a prognostic and therapeutic indicator for lung adenocarcinoma
Kazuya Takakuwa, Kaoru Mogushi, Min Han, Tomoaki Fujii, Masaki Hosoya, Arina Yamanami, Tomomi Akita, Chikamasa Yamashita, Tetsu Hayashida, Shunsuke Kato, Shigeo Yamaguchi
Scientific Reports.2020;[Epub]     CrossRef
Curcumin Suppresses Epithelial Growth Factor Receptor (EGFR) and Proliferative Protein (Ki 67) in Acute Lung Injury and Lung Fibrosis In vitro and In vivo
Sadiya Bi Shaikh, Ashwini Prabhu, Yashodhar Prabhakar Bhandary
Endocrine, Metabolic & Immune Disorders - Drug Targets.2020; 20(4): 558.     CrossRef
Integrated analysis of long non-coding RNAs and mRNA profiles reveals potential sex-dependent biomarkers of bevacizumab/erlotinib response in advanced lung cancer
Chao Tu, Yingqi Pi, Shan Xing, Yang Ling, Rama Krishna Kancha
PLOS ONE.2020; 15(10): e0240633.     CrossRef